A PHASE 1 STUDY IN HEALTHY VOLUNTEERS EXPLORING THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-450: A NOVEL ORAL MK2 INHIBITOR

被引：1
|
作者：
Schnyder, J. [1 ]
Monahan, J. [1 ]
Smith, W. [1 ]
Hope, H. [1 ]
Kelly, D. [1 ]
Burt, D. [1 ]
Huff, E. [1 ]
Kaul, A. [1 ]
Hildebrand, A. [1 ]
Burnette, B. [1 ]
Klug, N. [1 ]
Bangs, M. [1 ]
Gordon, D. [1 ]
机构：
[1] Aclaris Therapeut Inc, Wayne, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.5645
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0143
引用
收藏
页码：1006 / 1006
页数：1
相关论文
共 50 条
  • [1] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase I Study
    Gordon, David
    Hellriegel, Edward T.
    Hope, Heidi Rath
    Burt, David
    Monahan, Joseph B.
    [J]. CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2021, 13 : 123 - 134
  • [2] ATI-450: A Novel MK2 Pathway Inhibitor - Preclinical & Clinical Translational Studies to Predict Human Dose
    Hope, Heidi R.
    Hockerman, Susan
    Saabye, Matt
    Stillwell, Loreen
    Basavalingappa, Rakesh
    Emanual, Catherine
    Mnich, Steve
    Bangs, Madison
    Huff, Emma
    Kaul, Aparna
    Hildebrand, Anne
    Cardillo, Marco
    Aggarwal, Ajay
    Monahan, Joseph B.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385
  • [3] A Study of the Absorption, Metabolism, and Excretion of [14C]-ATI-450, an Investigational Oral MK2 Inhibitor Following a Single Dose
    Konen, Joe
    Lu, Jessea Wenjie
    Burt, David
    Monahan, Joseph
    DeCrescenzo, Gary
    Hellriegel, Edward
    Barnes, Brad
    Aggarwal, Ajay
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 256 - 257
  • [4] The Pharmacokinetics, Pharmacodynamics, and Safety of Baricitinib, an Oral JAK 1/2 Inhibitor, in Healthy Volunteers
    Shi, Jack G.
    Chen, Xuejun
    Lee, Fiona
    Emm, Thomas
    Scherle, Peggy A.
    Lo, Yvonne
    Punwani, Naresh
    Williams, William V.
    Yeleswaram, Swamy
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (12): : 1354 - 1361
  • [5] A Trial of MK2 Inhibitor ATI-450 in Patients with Moderate-Severe Novel Coronavirus Disease 2019 (COVID-19)
    Streiler, C.
    Jasahui, M. Postigo
    Nazir, U.
    Jandali, M.
    Lovell, K.
    Fruhauf, E.
    Brown, A.
    He, J.
    Hope, H.
    Monahan, J.
    Gordon, D.
    Castro, M.
    Polineni, D.
    Gan, G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [6] Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of Teneligliptin, a New DPP-IV Inhibitor, in Healthy Volunteers
    Kumagai, Yuji
    Fujita, Tomoe
    Kawaguchi, Atsuhiro
    Hayashi, Yoshiharu
    Kondou, Kazuoki
    [J]. DIABETES, 2010, 59 : A193 - A193
  • [7] A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
    Susanne Johansson
    David P. Rosenbaum
    Mikael Knutsson
    Maria Leonsson-Zachrisson
    [J]. Clinical and Experimental Nephrology, 2017, 21 : 407 - 416
  • [8] Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
    Al-Karagholi, Mohammad Al-Mandi
    Hansen, Jakob Moller
    Abou-Kassem, Dalia
    Hansted, Anna Koldbro
    Ubhayasekera, Kumari
    Bergquist, Jonas
    Vecsei, Laszlo
    Jansen-Olesen, Inger
    Ashina, Messoud
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (02):
  • [9] A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
    Johansson, Susanne
    Rosenbaum, David P.
    Knutsson, Mikael
    Leonsson-Zachrisson, Maria
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2017, 21 (03) : 407 - 416
  • [10] Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers
    Ramanathan, Srini
    Di Paolo, Julie A.
    Jin, Feng
    Shao, Lixin
    Sharma, Shringi
    Robeson, Michelle
    Kearney, Brian P.
    [J]. CLINICAL DRUG INVESTIGATION, 2017, 37 (02) : 195 - 205
12345